NASDAQ: CMPSCompass Pathways PLC Stock
$2.35-2.28 (-49.24%)
Updated Jun 23, 2025
CMPS Price
$2.35
Fair Value Price
$1.97
Market Cap
$219.87M
52 Week Low
$2.25
52 Week High
$8.54
P/E
-1.21x
P/B
1.12x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$137.80M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.63
Operating Cash Flow
-$144M
Beta
1.43
Next Earnings
Jul 30, 2025
Ex-Dividend
N/A
Next Dividend
N/A
CMPS Overview
COMPASS Pathways plc is a mental health care company in the U.K. and U.S. COMP360 is a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. Known as COMPASS Rx Limited until 2020/08, COMPASS Pathways was incorporated in 2020 and is headquartered in London, the U.K.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CMPS's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Care Facility
Industry Rating
B
CMPS
Ranked#40 of 42
Ranked#40 of 42
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $14.30 | A | |
| $9.28 | A | |
| $13.37 | A |
Be the first to know about important CMPS news, forecast changes, insider trades & much more!
CMPS News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CMPS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CMPS ($2.35) is overvalued by 19.34% relative to our estimate of its Fair Value price of $1.97 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CMPS ($2.35) is not significantly undervalued (19.34%) relative to our estimate of its Fair Value price of $1.97 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CMPS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CMPS due diligence checks available for Premium users.
Valuation
CMPS fair value
Fair Value of CMPS stock based on Discounted Cash Flow (DCF)
Price
$2.35
Fair Value
$1.97
Overvalued by
19.34%
CMPS ($2.35) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CMPS ($2.35) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CMPS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CMPS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.21x
Industry
16.55x
Market
31.56x
CMPS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.12x
Industry
4.57x
CMPS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CMPS's financial health
Profit margin
Revenue
$0.0
Net Income
-$17.9M
Profit Margin
0%
CMPS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$319.1M
Liabilities
$123.7M
Debt to equity
0.63
CMPS's short-term assets ($305.47M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CMPS's short-term assets ($305.47M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CMPS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$45.7M
Investing
$0.0
Financing
$140.4M
CMPS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CMPS vs Medical Care Facility Stocks
Compass Pathways Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.